[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100398130":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":36,"responsibleParty":70,"collaborators":10,"id":73,"slug":10,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuroendocrine toumor group",null,"30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.",[13],"Drug: Somatostatin analog; chemotherapy",{"label":15,"type":10,"description":16,"interventionNames":10},"Control group","Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Somatostatin analog; chemotherapy","According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.",[9],[24],{"name":25,"affiliation":26,"role":27},"Andrea M Isidori, MD, PhD","Department of Experimental Medicine, Sapienza University of Rome","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+390649970540","andrea.isidori@uniroma1.it",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Elisa M Giannetta, MD, PhD","elisa.giannetta@uniroma1.it",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":41,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Andrea M Isidori","RECRUITING","Rome","Italy","00161",{"type":44,"coordinates":45},"Point",[46,47],12.51133,41.89193,{"lat":47,"lon":46},[50,52,53,56,58,60,62,64,66,68],{"name":25,"role":30,"phone":51,"phoneExt":10,"email":32},"00390649970540",{"name":25,"role":27,"phone":10,"phoneExt":10,"email":10},{"name":54,"role":55,"phone":10,"phoneExt":10,"email":10},"Elisa Giannetta, MD, PhD","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":10,"phoneExt":10,"email":10},"Antongiulio Faggiano, MD, PhD",{"name":59,"role":55,"phone":10,"phoneExt":10,"email":10},"Mary Anna Venneri, PhD",{"name":61,"role":55,"phone":10,"phoneExt":10,"email":10},"Maria Grazia Tarsitano, MD, PhD",{"name":63,"role":55,"phone":10,"phoneExt":10,"email":10},"Giulia Puliani, MD",{"name":65,"role":55,"phone":10,"phoneExt":10,"email":10},"Tiziana Feola, MD",{"name":67,"role":55,"phone":10,"phoneExt":10,"email":10},"Franz Sesti, MD",{"name":69,"role":55,"phone":10,"phoneExt":10,"email":10},"Francesca Sciarra, PhD",{"type":27,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Andrea M. Isidori","Full Professor","100398130",false,"NCT04464122","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study","REBORN","Inclusion Criteria:\n\n* Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);\n* Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).\n\nExclusion Criteria:\n\n* Severe chronic kidney disease (stage 4-5);\n* Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;\n* Other non-neuroendocrine malignancies.","ALL","18 Years","80 Years",{"count":84,"type":85},60,"ESTIMATED","OBSERVATIONAL","This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.",[89,90,91,92,93],"Neuroendocrine Tumors","Neuroendocrine Neoplasm","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Carcinoma",[95,96,97,98,99],"Neuroendocrine Tumours","Prognostic markers","Tumour educated platelets","angiogenesis","immune function","2025-03-31",{"date":102,"type":103},"2025-04-03","ACTUAL",{"date":105,"type":103},"2020-09-14",{"date":107,"type":85},"2025-12-31",{"name":5,"class":6},1]